Re-boost Immunizations with the Peptide-based Therapeutic HIV Vaccine, Vacc-4x, Restores Geometric Mean Viral Load Set-point During Treatment Interruption

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2019 Jan 31

PMID 30699178

Citations 6

Authors

Jurgen K Rockstroh

David Asmuth

Giuseppe Pantaleo

Bonaventura Clotet

Daniel Podzamczer

Jan van Lunzen

Keikawus Arasteh

Ronald Mitsuyasu

Barry Peters

Nozza Silvia

Darren Jolliffe

Mats Okvist

Kim Krogsgaard

Maja A Sommerfelt

Affiliations

Soon will be listed here.

Abstract

Background: Vacc-4x, a therapeutic HIV vaccine candidate has previously induced a significant reduction in viral load (VL) set-point compared to placebo upon interruption of combination anti-retroviral therapy (ART) (2007/1 study). This study, (2012/1), explored the potential to maintain Vacc-4x effect by re-boosting eligible 2007/1 study participants.

Methods: Participant inclusion required 2007/1 participants to have completed all Vacc-4x immunizations and interrupted ART for up to 26 weeks. At weeks (wk)0 and 2, participants received intradermal (i.d.) Vacc-4x booster immunizations (1.2mg) on ART with GM-CSF (60μg) i.d. as a local adjuvant. ART was interrupted for up to 16 weeks (wk12-wk28). Participants were then followed on ART until wk36. VL set-point, total proviral DNA (pvDNA) and immunogenicity assessed by IFN-γ ELISPOT, T-cell proliferation and delayed type hypersensitivity (DTH) reactions were compared to participants' values in the 2007/1 study where available.

Results: This open, multicenter, clinical study enrolled 33 participants from 9 clinical trial sites in the US and Europe. In the per-protocol (PP) population, the VL set-point geometric mean (GM) 18162 copies/mL was not significantly changed compared to the 2007/1 study (GM VL 22035 copies/mL), (p = 0.453, n = 18). For participants with available preART VL values, the VL set-point (GM 26279 copies/mL) remained significantly lower than the preART VL set-point (GM 74048 copies/mL, p = 0.021, n = 13). A statistically significant reduction in pvDNA (49%) from baseline to wk4 was observed (p = 0.03, n = 26). DTH responses (wk4) increased significantly from baseline (p = 0.006, n = 30) and compared to the 2007/1 study (p = 0.022, n = 29) whilst the proportion of participants with ELISPOT and T-cell proliferation responses was similar between the two studies.

Conclusions: Vacc-4x booster immunizations safely maintained the mean VL set-point at that established following primary Vacc-4x therapeutic immunization. The reduction in pvDNA during ART supports the potential for Vacc-4x immunization to reduce HIV reservoirs and thereby contribute to combination HIV cure strategies.

Citing Articles

Conserved multiepitope vaccine constructs: A potent HIV-1 therapeutic vaccine in clinical trials.

Akbari E, Seyedinkhorasani M, Bolhassani A Braz J Infect Dis. 2023; 27(3):102774.

PMID: 37156468 PMC: 10188636. DOI: 10.1016/j.bjid.2023.102774.

Different Methods and Formulations of Drugs and Vaccines for Nasal Administration.

Tai J, Han M, Lee D, Park I, Lee S, Kim T Pharmaceutics. 2022; 14(5).

PMID: 35631663 PMC: 9144811. DOI: 10.3390/pharmaceutics14051073.

Peptides for Vaccine Development.

Hamley I ACS Appl Bio Mater. 2022; 5(3):905-944.

PMID: 35195008 PMC: 9384901. DOI: 10.1021/acsabm.1c01238.

So Pathogenic or So What?-A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research.

Kleinman A, Pandrea I, Apetrei C Viruses. 2022; 14(1).

PMID: 35062339 PMC: 8781889. DOI: 10.3390/v14010135.

ART-Treated Patients Exhibit an Adaptive Immune Response against the HFVAC Peptides, a Potential HIV-1 Therapeutic Vaccine (Provir/Latitude45 Study).

Fleury H, Caldato S, Recordon-Pinson P, Thebault P, Guidicelli G, Hessamfar M Viruses. 2020; 12(11).

PMID: 33167335 PMC: 7694376. DOI: 10.3390/v12111256.

References

Hunt P, Lee S, Siedner M . Immunologic Biomarkers, Morbidity, and Mortality in Treated HIV Infection. J Infect Dis. 2016; 214 Suppl 2:S44-50. PMC: 5021241. DOI: 10.1093/infdis/jiw275. View

Leth S, Schleimann M, Nissen S, Hojen J, Olesen R, Graversen M . Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial. Lancet HIV. 2016; 3(10):e463-72. DOI: 10.1016/S2352-3018(16)30055-8. View

Nyhus J, Kran A, Sommerfelt M, Baksaas I, Sorensen B, Kvale D . Multiple antigen concentrations in delayed-type hypersensitivity (DTH) and response diversity during and after immunization with a peptide-based HIV-1 immunotherapy candidate (Vacc-4x). Vaccine. 2005; 24(10):1543-50. DOI: 10.1016/j.vaccine.2005.10.012. View

Sogaard O, Graversen M, Leth S, Olesen R, Brinkmann C, Nissen S . The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo. PLoS Pathog. 2015; 11(9):e1005142. PMC: 4575032. DOI: 10.1371/journal.ppat.1005142. View

Fletcher C, Staskus K, Wietgrefe S, Rothenberger M, Reilly C, Chipman J . Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues. Proc Natl Acad Sci U S A. 2014; 111(6):2307-12. PMC: 3926074. DOI: 10.1073/pnas.1318249111. View

Maldarelli F, Wu X, Su L, Simonetti F, Shao W, Hill S . HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science. 2014; 345(6193):179-83. PMC: 4262401. DOI: 10.1126/science.1254194. View

Clarridge K, Blazkova J, Einkauf K, Petrone M, Refsland E, Justement J . Effect of analytical treatment interruption and reinitiation of antiretroviral therapy on HIV reservoirs and immunologic parameters in infected individuals. PLoS Pathog. 2018; 14(1):e1006792. PMC: 5764487. DOI: 10.1371/journal.ppat.1006792. View

Karlsson A, Birk M, Lindback S, Gaines H, Mittler J, Sonnerborg A . Initiation of therapy during primary HIV type 1 infection results in a continuous decay of proviral DNA and a highly restricted viral evolution. AIDS Res Hum Retroviruses. 2001; 17(5):409-16. DOI: 10.1089/088922201750102463. View

Oxenius A, Price D, Gunthard H, Dawson S, Fagard C, Perrin L . Stimulation of HIV-specific cellular immunity by structured treatment interruption fails to enhance viral control in chronic HIV infection. Proc Natl Acad Sci U S A. 2002; 99(21):13747-52. PMC: 129766. DOI: 10.1073/pnas.202372199. View

10.

Seddiki N, Levy Y . Therapeutic HIV-1 vaccine: time for immunomodulation and combinatorial strategies. Curr Opin HIV AIDS. 2018; 13(2):119-127. DOI: 10.1097/COH.0000000000000444. View

11.

Garcia F, Climent N, Guardo A, Gil C, Leon A, Autran B . A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci Transl Med. 2013; 5(166):166ra2. DOI: 10.1126/scitranslmed.3004682. View

12.

Pollard R, Rockstroh J, Pantaleo G, Asmuth D, Peters B, Lazzarin A . Safety and efficacy of the peptide-based therapeutic vaccine for HIV-1, Vacc-4x: a phase 2 randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2014; 14(4):291-300. DOI: 10.1016/S1473-3099(13)70343-8. View

13.

McElrath M, Corey L, Berger D, HOFFMAN M, Klucking S, Dragavon J . Immune responses elicited by recombinant vaccinia-human immunodeficiency virus (HIV) envelope and HIV envelope protein: analysis of the durability of responses and effect of repeated boosting. J Infect Dis. 1994; 169(1):41-7. DOI: 10.1093/infdis/169.1.41. View

14.

Eisinger R, Fauci A . Ending the HIV/AIDS Pandemic. Emerg Infect Dis. 2018; 24(3):413-416. PMC: 5823353. DOI: 10.3201/eid2403.171797. View

15.

Psomas C, Fidler S, Macartney M, Jeffreys R, Reilly L, Collins S . Highlights from the 22nd International AIDS Conference (AIDS 2018), 22-27 July 2018, Amsterdam, the Netherlands. J Virus Erad. 2018; 4(4):238-247. PMC: 6248835. View

16.

Persaud D, Gay H, Ziemniak C, Chen Y, Piatak Jr M, Chun T . Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med. 2013; 369(19):1828-35. PMC: 3954754. DOI: 10.1056/NEJMoa1302976. View

17.

Cohen M, Chen Y, McCauley M, Gamble T, Hosseinipour M, Kumarasamy N . Antiretroviral Therapy for the Prevention of HIV-1 Transmission. N Engl J Med. 2016; 375(9):830-9. PMC: 5049503. DOI: 10.1056/NEJMoa1600693. View

18.

Lind A, Brekke K, Sommerfelt M, Holmberg J, Aass H, Baksaas I . Boosters of a therapeutic HIV-1 vaccine induce divergent T cell responses related to regulatory mechanisms. Vaccine. 2013; 31(41):4611-8. DOI: 10.1016/j.vaccine.2013.07.037. View

19.

Vardas E, Stanescu I, Leinonen M, Ellefsen K, Pantaleo G, Valtavaara M . Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU(®)-Multi-HIVB, in untreated HIV-1 infected subjects. Vaccine. 2012; 30(27):4046-54. DOI: 10.1016/j.vaccine.2012.04.007. View

20.

Huang Y, Zhang L, Jolliffe D, Hovden A, Okvist M, Pantaleo G . A case for preART-adjusted endpoints in HIV therapeutic vaccine trials. Vaccine. 2016; 34(10):1282-8. DOI: 10.1016/j.vaccine.2016.01.025. View